AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27680219
Drug: Standard/low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard/low dose regimen starting at 70% of the minimal erythema dose (MED) with 20% dose increments
Trial: 27680219
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose regimen starting at 200% MED with 25% increments
Trial: 15823771
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg sachet for suspension
Trial: 15823771
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg capsule
Trial: 15823771
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg sachet for suspension
Trial: 15823771
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg capsule
Trial: 9466101
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.5% plain bupivacaine
Trial: 9466101
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.9% saline with 5 mg diamorphine
Trial: 9466101
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.9% saline (control)
Trial: 8180744
Drug: Picotamide (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (1200 mg/day)
Trial: 3286360
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg twice daily
Trial: 31747236
Drug: FF/VI 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100 mcg/25 mcg
Trial: 26291137
Drug: FF 100
RxNorm normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF 100 mcg
Trial: 26445112
Drug: Glucagon +
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon + GLP-1 (same doses)
Trial: 26445112
Drug: All peptide
RxNorm normalized name: Fibrin degradation agent, small peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All peptide infusions
Trial: 24019546
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation therapy (EBRT) following vaginal radium brachytherapy (n = 288)
Trial: 22010012
Drug: S-1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80 to 120 mg per day for 4 weeks, followed by 2 weeks of rest, repeated for 1 year)
Trial: 19564224
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment recommended by the Chilean Ministry of Health
Trial: 16458130
Drug: downstream high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: downstream high-dose bolus tirofiban
Trial: 15303805
Drug: Intra‐articular corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐articular corticosteroid injections (ICIs)
Trial: 28385329
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin (BP) - 600,000 IU for children ≤27kg and 1,200,000 IU for children ≥27kg, administered every two weeks for six months.
Trial: 28385329
Drug: Azithromycin (AZT)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZT) - 250mg for children ≤25kg and 500mg for children ≥25kg, administered once weekly for six months.
Trial: 23233715
Drug: modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified FOLFOX6 plus bevacizumab (5 mg/kg) once every 2 weeks for 12 months
Trial: 10429840
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg/day by oral inhalation for 28 days
Trial: 7724714
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for major depression in primary care setting
Trial: 1823578
Drug: Antioxidant compound
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant compound (2 tablets daily for 3 weeks)
Trial: 7033994
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosage of carbamazepine (mean dose 13.9 mg/dg)
Trial: 7033994
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosage of carbamazepine
Trial: 7033994
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily doses of carbamazepine (2 to 3 times daily)
Trial: 6145618
Drug: Pafenolol (beta-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pafenolol (beta-blocker more beta 1-selective than metoprolol)
Trial: 6145618
Drug: Prenalterol (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (selective beta 1-stimulating agent)
Trial: 23312051
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (3 g/day, 1 g three times a day during meals for 6 months)
Trial: 22945778
Drug: Lubricant gel
RxNorm normalized name: Surgilube Lubricant Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricant gel
Trial: 21966755
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day (group 1)
Trial: 21966755
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day plus chlormadinone 1 mg/day (group 2)
Trial: 12962026
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) administered every month or two months for more than half a year
Trial: 9869584
Drug: 3-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day regimen of oral azithromycin (500 mg/day for days 1 to 3)
Trial: 9869584
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of oral azithromycin (500 mg on day 1 and 250 mg/day for days 2 to 5)
Trial: 9869584
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens of oral azithromycin
Trial: 30865288
Drug: Smartphone-based daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based daily evaluation of mixed symptoms and irritability
Trial: 30383906
Drug: nab-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14
Trial: 30383906
Drug: single-agent nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8
Trial: 27271664
Drug: 400 g
RxNorm normalized name: Ambi 60 PSE-400 GFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 g of olive fruit polyphenol-enriched yogurt with 50 mg of encapsulated olive polyphenols
Trial: 27271664
Drug: 400 g
RxNorm normalized name: Ambi 60 PSE-400 GFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 g of plain yogurt
Trial: 23485658
Drug: Preoperative education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative education and administration of intramuscular diclofenac Na 75 mg regardless of pain reporting in the first two postoperative hours
Trial: 23485658
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received no preoperative education and analgesics only upon pain reporting
Trial: 21824010
Drug: ASCT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCT treatment (MPD plus RCT)
Trial: 22933843
Drug: Integrated Treatment
RxNorm normalized name: Bag Spike + Integrated Clave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Treatment
Trial: 16312171
Drug: 0.4% olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% olopatadine nasal spray
Trial: 16312171
Drug: 0.6% olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% olopatadine nasal spray
Trial: 16400902
Drug: Olopatadine nasal
RxNorm normalized name: olopatadine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine nasal spray (0.4% and 0.6%)
Trial: 9532321
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (42 mcg/nostril t.i.d.)
Trial: 9532321
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (84 mcg/nostril t.i.d.)
Trial: 3288292
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g pulsed methylprednisolone
Trial: 3288292
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg pulsed methylprednisolone
Trial: 3288292
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pulsed methylprednisolone
Trial: 12305415
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dienestrol following each intercourse
Trial: 12305415
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg dienestrol and 0.2 mg ethynodiol‐diacetate
Trial: 19829284
Drug: 5-HT3 antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT3 antagonists
Trial: 30684048
Drug: Neuroleptic antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic antipsychotics
Trial: 25723472
Drug: Control (lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (lopinavir/ritonavir with nucleoside/nucleotide reverse transcriptase inhibitors)
Trial: 3530858
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Acarbose with 100 g sucrose load
Trial: 3530858
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 100 g sucrose load
Trial: 30328494
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (10 IU in 500 ml saline at 120 ml/h)
Trial: 17473774
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (3.6 g.kg(‐1); HP)
Trial: 17473774
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.8 g.kg(‐1); LP)
Trial: 17473774
Drug: Moderate-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-protein diet (1.8 g.kg(‐1); MP)
Trial: 15051932
Drug: AST-120 (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (6.0 g/day)
Trial: 11576048
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 microg x kg(‐1) x min(‐1)) combined with propofol (target plasma concentration of 1.5 microg x ml(‐1))
Trial: 28081288
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (6 mm; GS/group short)
Trial: 28081288
Drug: Long implants
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long implants (11-15 mm; GG/group graft)
Trial: 25884448
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of neo‐adjuvant oxaliplatin‐based chemotherapy followed by surgery (arm B)
Trial: 25884448
Drug: Surgery alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery alone (standard treatment, arm A)
Trial: 3169371
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg standard release disopyramide given three times daily
Trial: 3169371
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg sustained release disopyramide given twice daily
Trial: 27110697
Drug: Sirukumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab (10 mg/kg intravenously every 4 weeks through week 24)
Trial: 19064574
Drug: Flaxseed-supplemented diet
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed-supplemented diet (30 g/d)
Trial: 14520146
Drug: Linezolid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (10 mg/kg for patients <12 years; 600 mg for patients ≥12 years, intravenous/oral, 2-3 times daily)
Trial: 7967990
Drug: Oral inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inactivated whole-cell/recombinant-B-subunit cholera vaccine (WC/rBS)
Trial: 3304929
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg at night + 200 mg ofloxacin twice daily
Trial: 18650827
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 or 100 mg) nightly for 36 weeks
Trial: 8625230
Drug: PAM (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAM (cisplatin 60 mg/m2 i.v. on Days 1 and 29; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Trial: 8625230
Drug: FAM (5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM (5‐fluorouracil 600 mg/m2 i.v. on Days 1, 8, 29, 36; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Trial: 27941065
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg daily)
Trial: 23631796
Drug: Inhaled glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glutathione (646 mg in 4 ml) administered every 12 hours for 6 months
Trial: 15837905
Drug: Brandt‐Daroff exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brandt‐Daroff exercises (treatment group, n = 43)
Trial: 15837905
Drug: No exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exercises (no-treatment group, n = 73)
Trial: 15837905
Drug: Brandt‐Daroff exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brandt‐Daroff exercises (treatment group)
Trial: 15837905
Drug: No exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exercises (no-treatment group)
Trial: 12898489
Drug: Pharmacy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy group (prescription for azithromycin to be filled at a local pharmacy)
Trial: 10566643
Drug: Dietary soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary soy supplementation (60 g, 45 mg isoflavones)
Trial: 8739813
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg tablet, three times daily for 3 months (TID group)
Trial: 8739813
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release nicardipine, 50 mg twice daily for 3 months (BID group)
Trial: 7014726
Drug: new chromone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: new chromone compound
Trial: 26871534
Drug: Negative hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative hypnotic suggestions (based on the Pain Catastrophizing Scale)
Trial: 26871534
Drug: Positive hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive hypnotic suggestions (coping-oriented reversion of the Pain Catastrophizing Scale)
Trial: 26871534
Drug: Neutral hypnotic
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral hypnotic suggestions (neutral sentence)
Trial: 22709750
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management intervention
Trial: 15174784
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide treatment
Trial: 15727381
Drug: Zolterol, SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolterol, SR (generic diclofenac sodium sustained release tablet)
Trial: 9534106
Drug: slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release verapamil 240 mg/day
Trial: 11910310
Drug: trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trandolapril 2 mg/day
Trial: 9534106
Drug: verapamil 180
RxNorm normalized name: verapamil 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 180 mg/day plus trandolapril 2 mg/day
Trial: 9534106
Drug: trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trandolapril 2 mg/day plus verapamil 180 mg/day
Trial: 7661587
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care plus combination chemotherapy
Trial: 2693623
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic combination (gentamicin, clindamycin, penicillin G)
Trial: 28537195
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg kg-1)
Trial: 21441549
Drug: Morphine patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient-controlled analgesia (PCA)
Trial: 19363377
Drug: Psychosocial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial treatment for MA dependence
Trial: 12095667
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 120, 240, and 480 mg/day
Trial: 2530546
Drug: IV ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ceftriaxone 2 g daily for 4 days, followed by IM or IV ceftriaxone 1 g daily for 11 days
Trial: 2530546
Drug: IV ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ceftriaxone 2 g every other day for 4 days, followed by oral cefixime 200 mg twice daily for 11 days
Trial: 25769319
Drug: Ji‐Tai tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ji‐Tai tablet
Trial: 25769319
Drug: Ji‐Tai tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ji‐Tai tablet combined with buprenorphine
Trial: 23810466
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + S-1 (paclitaxel 60 mg/m2 on days 1, 8, and 15; S-1 80-120 mg/d on days 1-14)
Trial: 23810466
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + S-1
Trial: 23810466
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + 5-fluorouracil (paclitaxel 60 mg/m2; 5-fluorouracil 500 mg/m2 on days 1-5; leucovorin 20 mg/m2 on days 1-5)
Trial: 23810466
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + 5-fluorouracil
Trial: 20587723
Drug: 2-h hyperinsulinemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h hyperinsulinemic hypoglycemia (2.9 ± 0.1 mmol/l)
Trial: 20587723
Drug: Euglycemia (5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (5.2 ± 0.1 mmol/l)
Trial: 18249205
Drug: 22 mg
RxNorm normalized name: urea 0.22 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg PSs per kilogram of body weight with a low‐cholesterol diet (C(‐)S(+))
Trial: 18249205
Drug: 22 mg
RxNorm normalized name: urea 0.22 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg PSs per kilogram of body weight with a high‐cholesterol diet (C(+)S(+))
Trial: 18249205
Drug: 22 mg
RxNorm normalized name: urea 0.22 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg PSs per kilogram of body weight (both diets)
Trial: 10389720
Drug: Weekly stress
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly stress incontinence
Trial: 10389720
Drug: Weekly urge
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly urge incontinence
Trial: 1988575
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (chemotherapy and tamoxifen)